GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Fatty Liver Disease/FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2026

Quick Answer

The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This study highlights the utility of FIB-4 as a noninvasive marker that can stratify cardiovascular risk and guide clinical decision-making in MASLD patients.


The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This study highlights the utility of FIB-4 as a noninvasive marker that can stratify cardiovascular risk and guide clinical decision-making in MASLD patients.

### Key Findings:

1. **Association Between MASLD and CAC**:

  • Individuals with MASLD were found to have a higher prevalence of coronary artery calcification compared to those without MASLD.
  • This suggests that MASLD, which is characterized by steatotic liver disease and cardiometabolic risk factors, is closely linked to coronary atherosclerosis.

2. **Role of FIB-4 Index**:

  • The FIB-4 index, a simple calculation based on age, platelet count, AST (aspartate aminotransferase), and ALT (alanine aminotransferase), was used to estimate liver fibrosis severity.
  • Higher FIB-4 values were associated with more advanced coronary calcification, indicating a greater risk of coronary artery disease (CAD).
  • Conversely, lower FIB-4 values were effective in identifying individuals at low risk of severe CAC.

3. **Progressive Risk in MASLD**:

  • In MASLD patients, increasing liver fibrosis severity (reflected by higher FIB-4 values) corresponded with progressively higher coronary calcium levels.
  • This relationship underscores the interconnectedness of liver fibrosis and cardiometabolic burden in driving coronary atherosclerosis.

### Clinical Implications:

  • **Risk Stratification**:
  • FIB-4 can serve as a practical, noninvasive index to stratify cardiovascular risk in MASLD patients. Elevated FIB-4 values may identify individuals who require closer cardiovascular monitoring and intervention.
  • Patients with low FIB-4 scores may be considered at lower risk for severe CAC, potentially reducing the need for more invasive diagnostic procedures.
  • **Early Preventive Care**:
  • Routine use of the FIB-4 index in MASLD patients can guide early preventive measures to mitigate cardiovascular risk, including lifestyle modifications, pharmacological interventions, and closer monitoring for coronary artery disease.
  • **Integration in Clinical Practice**:
  • The FIB-4 index is inexpensive, widely accessible, and easy to calculate, making it a feasible tool for routine use in primary care and specialized settings.

### Conclusion:

The study underscores the clinical utility of the FIB-4 index as a referral index for coronary artery calcification in MASLD patients. By identifying individuals at increased risk of coronary atherosclerosis, FIB-4 can help optimize cardiovascular risk stratification and facilitate early preventive care. This approach may ultimately improve long-term outcomes for patients with MASLD and associated cardiometabolic conditions.

Related Q&A

Type 2 Diabetes Accelerates Liver Fibrosis in Chronic Hepatitis B with Fatty Liver: Hepatology | May 2026

Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...

A Novel Gut-Targeted Therapy for MASH (DT-109): Journal of Clinical Investigation | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...

DT-109- A Novel Gut-Targeted Therapy for MASH: JCI | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...

Tirzepatide vs SGLT2i in MASLD: Hepatology International | July 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...

Early Weight Regain After GLP-1 RA Discontinuation: Diabetes, Obesity and Metabolism | July 2026

Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...

Incretin-Based Therapy for MASH: Metabolic Target Organ Damage | July 2026

Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer